FAQ: Kairos Pharma's ENV-105 Phase 2 Results in Advanced Prostate Cancer

What is ENV-105 and what does it treat?

ENV-105 (carotuximab) is Kairos Pharma’s lead antibody candidate that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. It is currently in Phase 2 trials for metastatic castration-resistant prostate cancer and Phase 1 trials for lung cancer.

What were the key findings from the Phase 2 trial?

The interim results showed clinical benefit in 86% of patients treated with ENV-105 combined with apalutamide, with all responders remaining progression-free for at least four months and half beyond one year. Seven of nine evaluable patients experienced PSA reductions, supporting the therapy’s potential to restore hormone responsiveness.

Why are these results significant for prostate cancer patients?

These results are significant because they demonstrate ENV-105’s potential to reverse drug resistance and restore the effectiveness of standard therapies in metastatic castration-resistant prostate cancer, addressing a major unmet medical need where patients typically develop resistance to existing treatments.

How does ENV-105 work to fight cancer?

ENV-105 targets CD105, a protein that becomes elevated in response to standard cancer therapy and causes resistance and disease relapse. By targeting CD105, ENV-105 aims to reverse this drug resistance and restore the effectiveness of standard cancer treatments.

Who conducted this clinical trial and where was it presented?

The randomized Phase 2 trial is led by Cedars-Sinai and partner institutions, and the interim results were presented at the European Society for Medical Oncology meeting in Berlin.

What is Kairos Pharma’s focus as a company?

Kairos Pharma is a clinical-stage biopharmaceutical company based in Los Angeles, California that focuses on developing innovative cancer therapeutics using structural biology to overcome drug resistance and immune suppression in cancer.

Where can I find more detailed information about these results?

The full press release is available at https://ibn.fm/1KEqw, and the latest news and updates relating to Kairos Pharma (KAPA) are available in the company’s newsroom at https://ibn.fm/KAPA.

What is the current status of ENV-105’s clinical development?

ENV-105 is currently in an ongoing Phase 2 clinical trial for castrate-resistant prostate cancer that continues to enroll patients to further evaluate safety and long-term efficacy, and is also in a Phase 1 trial for lung cancer.